CANbridge Pharmaceuticals CAN108 new drug application for Alagille syndrome accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals

17 January 2022 - Priority review expected to be granted.

CANbridge Pharmaceuticals announced today that the Chinese National Medical Products Administration (NMPA) has accepted the new drug application for CAN108 (maralixibat oral solution (Livmarli) for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Read CANbridge Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Dossier , China